FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2108336499> ?p ?o ?g. }

• W2108336499 endingPage "2207" @default.
• W2108336499 startingPage "2201" @default.
• W2108336499 abstract "BackgroundOn average, aromatase inhibitors are better than tamoxifen when used as initial or sequential therapy for postmenopausal women with endocrine-responsive early breast cancer. Because there may be contraindications to their use based on side-effects or cost, we investigated subgroups in which aromatase inhibitors may be more or less important.Patients and methodsBreast International Group 1-98 trial randomized 6182 women among four groups comparing letrozole and tamoxifen with sequences of each agent; 5177 (84%) had centrally confirmed estrogen receptor (ER) positivity. We assessed whether centrally determined ER, progesterone receptor (PgR), human epidermal growth factor receptor 2, and Ki-67 labeling index, alone or in combination with other prognostic features, predicted the magnitude of letrozole effectiveness compared with either sequence or tamoxifen monotherapy.ResultsIndividually, none of the markers significantly predicted differential treatment effects. Subpopulation treatment effect pattern plot analysis of a composite measure of prognostic risk revealed three patterns. Estimated 5-year disease-free survival for letrozole monotherapy, letrozole→tamoxifen, tamoxifen→letrozole, and tamoxifen monotherapy were 96%, 94%, 93%, and 94%, respectively, for patients at lowest risk; 90%, 91%, 93%, and 86%, respectively, for patients at intermediate risk; and 80%, 76%, 74%, and 69%, respectively, for patients at highest risk.ConclusionA composite measure of risk informs treatment selection better than individual biomarkers and supports the choice of 5 years of letrozole for patients at highest risk for recurrence." @default.
• W2108336499 created "2016-06-24" @default.
• W2108336499 creator A5001188276 @default.
• W2108336499 creator A5004597282 @default.
• W2108336499 creator A5015900909 @default.
• W2108336499 creator A5018625601 @default.
• W2108336499 creator A5025375068 @default.
• W2108336499 creator A5036344172 @default.
• W2108336499 creator A5038698814 @default.
• W2108336499 creator A5042046866 @default.
• W2108336499 creator A5053376791 @default.
• W2108336499 creator A5057819090 @default.
• W2108336499 creator A5058767202 @default.
• W2108336499 creator A5061698687 @default.
• W2108336499 creator A5068846522 @default.
• W2108336499 creator A5071541231 @default.
• W2108336499 creator A5074106135 @default.
• W2108336499 creator A5075159048 @default.
• W2108336499 creator A5083143792 @default.
• W2108336499 creator A5088697304 @default.
• W2108336499 creator A5089973122 @default.
• W2108336499 date "2011-10-01" @default.
• W2108336499 modified "2023-10-18" @default.
• W2108336499 title "Which patients benefit most from adjuvant aromatase inhibitors? Results using a composite measure of prognostic risk in the BIG 1-98 randomized trial" @default.
• W2108336499 cites W1531964529 @default.
• W2108336499 cites W1965192399 @default.
• W2108336499 cites W1995470900 @default.
• W2108336499 cites W1995836816 @default.
• W2108336499 cites W2015473392 @default.
• W2108336499 cites W2021723847 @default.
• W2108336499 cites W2097255042 @default.
• W2108336499 cites W2121863992 @default.
• W2108336499 cites W2127057139 @default.
• W2108336499 cites W2131964282 @default.
• W2108336499 cites W2131994307 @default.
• W2108336499 cites W2136655134 @default.
• W2108336499 cites W2146194560 @default.
• W2108336499 cites W2152190583 @default.
• W2108336499 cites W2155803397 @default.
• W2108336499 cites W2156604663 @default.
• W2108336499 cites W2157840751 @default.
• W2108336499 cites W2171638840 @default.
• W2108336499 doi "https://doi.org/10.1093/annonc/mdq738" @default.
• W2108336499 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3179413" @default.
• W2108336499 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/21335417" @default.
• W2108336499 hasPublicationYear "2011" @default.
• W2108336499 type Work @default.
• W2108336499 sameAs 2108336499 @default.
• W2108336499 citedByCount "80" @default.
• W2108336499 countsByYear W21083364992012 @default.
• W2108336499 countsByYear W21083364992013 @default.
• W2108336499 countsByYear W21083364992014 @default.
• W2108336499 countsByYear W21083364992015 @default.
• W2108336499 countsByYear W21083364992016 @default.
• W2108336499 countsByYear W21083364992017 @default.
• W2108336499 countsByYear W21083364992018 @default.
• W2108336499 countsByYear W21083364992019 @default.
• W2108336499 countsByYear W21083364992020 @default.
• W2108336499 countsByYear W21083364992021 @default.
• W2108336499 countsByYear W21083364992022 @default.
• W2108336499 countsByYear W21083364992023 @default.
• W2108336499 crossrefType "journal-article" @default.
• W2108336499 hasAuthorship W2108336499A5001188276 @default.
• W2108336499 hasAuthorship W2108336499A5004597282 @default.
• W2108336499 hasAuthorship W2108336499A5015900909 @default.
• W2108336499 hasAuthorship W2108336499A5018625601 @default.
• W2108336499 hasAuthorship W2108336499A5025375068 @default.
• W2108336499 hasAuthorship W2108336499A5036344172 @default.
• W2108336499 hasAuthorship W2108336499A5038698814 @default.
• W2108336499 hasAuthorship W2108336499A5042046866 @default.
• W2108336499 hasAuthorship W2108336499A5053376791 @default.
• W2108336499 hasAuthorship W2108336499A5057819090 @default.
• W2108336499 hasAuthorship W2108336499A5058767202 @default.
• W2108336499 hasAuthorship W2108336499A5061698687 @default.
• W2108336499 hasAuthorship W2108336499A5068846522 @default.
• W2108336499 hasAuthorship W2108336499A5071541231 @default.
• W2108336499 hasAuthorship W2108336499A5074106135 @default.
• W2108336499 hasAuthorship W2108336499A5075159048 @default.
• W2108336499 hasAuthorship W2108336499A5083143792 @default.
• W2108336499 hasAuthorship W2108336499A5088697304 @default.
• W2108336499 hasAuthorship W2108336499A5089973122 @default.
• W2108336499 hasBestOaLocation W21083364991 @default.
• W2108336499 hasConcept C121608353 @default.
• W2108336499 hasConcept C126322002 @default.
• W2108336499 hasConcept C143998085 @default.
• W2108336499 hasConcept C168563851 @default.
• W2108336499 hasConcept C2775860665 @default.
• W2108336499 hasConcept C2776166826 @default.
• W2108336499 hasConcept C2777176818 @default.
• W2108336499 hasConcept C2778504769 @default.
• W2108336499 hasConcept C2778812593 @default.
• W2108336499 hasConcept C29456083 @default.
• W2108336499 hasConcept C530470458 @default.
• W2108336499 hasConcept C71924100 @default.
• W2108336499 hasConcept C84606932 @default.
• W2108336499 hasConceptScore W2108336499C121608353 @default.
• W2108336499 hasConceptScore W2108336499C126322002 @default.
• W2108336499 hasConceptScore W2108336499C143998085 @default.

• next